EHA 2023 | Advances in BTK and BCL2 inhibitors for CLL
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the latest advances in the field of BTK and BCL2 inhibitors, commenting on first- and second-generation BTK inhibitors as well as BTK degraders, novel BCL2 inhibitors, and the potential of combination and time-limited therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
JRB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Alloplex Biotherapeutics, BeiGene, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, Kite, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, TG Therapeutics.
